Iridex Q1-2018 Revenues Decrease 9 Percent following Recall

May 4, 2018: By Jon Swedien

Iridex’ revenues for Q1-2018 were $9.5 million, down 9 percent compared with Q1-2017 revenues, the Mountain View, California, company reported May 3.

The company said the decrease in revenues was primarily due to its voluntary recall of its TruFocus LIO Premiere laser indirect ophthalmoscope.

Iridex issued the recall after reports of adverse events during procedures using the laser accessory, including focal cataracts and iris burns. The LIO is a head-mounted indirect ophthalmoscope that connects to an Iridex laser console and is used to view and perform laser treatments.

The decrease was partially offset by growth from G6 product revenues, Iridex said.

In Q1-2018, Iridex shipped 99 Cyclo G6 systems—compared with 64 in Q1-2017—and a record 11,600 G6 probes—compared with 6,600 in Q1-2017—the company said. The laser system is designed to reduce intraocular pressure without incisions or implants, potentially extending the time before more invasive measures are required.

Iridex had cash and cash equivalents of $18.5 million as of March 31, the company reported.

The company provided revenue guidance of $37 million to $41 million for the full year.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023